FDA Considers Recommending Johnson and Johnson COVID-19 Vaccine

The US Food and Drug Administration (FDA) will hold a meeting on Friday to decide whether they will recommend Johnson & Johnson’s COVID-19 vaccine for emergency use authorization.

J&J’s vaccine is the third to be considered by US health care officials, and is the only single-dose vaccine available on the market. All other vaccines involve a multi-does process, spread out over a few weeks.

Currently, J&J’s vaccine is shown to be 66.1% effective at preventing the spread of COVID-19 at least 28 days after receiving a dose.

Clinical trial investigators are confident the vaccine will receive FDA approval, noting that they had no major concerns. Dr. Jeff Carson, co-leader of the Rutgers Biomedical and Health Sciences, said that the vaccine worked well to prevent most “severe” forms of the disease as observed in his 800 participant clinical trial. 

Dr. Richard Nettles of J&J said that they would begin shipment as soon as emergency authorization was granted and that their goal was to vaccinate 20 million Americans by March 2021. Initial reserves of the vaccine are estimated to be around single-digit millions, according Biden’s White House administration. 

© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.